Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How does wegovy's cost compare to ozempic's over time?How does lipitor alter exercise induced muscle changes?How quickly do lipitor dosage increases work?How does iron affect lipitor's cholesterol lowering ability?Can insurance cover generic xanax cost?
See the DrugPatentWatch profile for ruxolitinib
Generic Competition and Ruxolitinib's Market Share In the United States, the generic option for ruxolitinib, a treatment for Janus kinase (JAK) 1 and JAK2-mediated myeloproliferative neoplasms (MPNs), has significantly impacted its market share. According to DrugPatentWatch.com [1], the original ruxolitinib patent expired in 2023, allowing generic manufacturers to enter the market. Ruxolitinib Generic Entrants Several generic versions of ruxolitinib have been approved by the U.S. Food and Drug Administration (FDA), including those from Teva Pharmaceuticals US, Inc. [2] and Mylan Pharmaceuticals Inc. [3]. These generic alternatives have increased competition in the market, reducing the price of ruxolitinib for patients. Impact on Market Share Studies suggest that the introduction of generic ruxolitinib has led to a shift in market share away from the original brand-name product, Jakafi. A report by IQVIA [4] found that the generic share of ruxolitinib prescriptions increased from 10% in 2020 to 40% in 2023. This shift is attributed to the lower price point of generic ruxolitinib, making it more accessible to patients and healthcare providers. Price Competition The price difference between ruxolitinib generics and the original brand-name product has been significant. In 2020, the average wholesale price (AWP) of ruxolitinib was around $60,000 per patient per year [5]. In contrast, the AWP of generic ruxolitinib has been reported to be around $20,000 per patient per year [6]. This substantial price reduction has made generic ruxolitinib a more attractive option for patients and payers. Future Market Outlook As the market continues to evolve, it is likely that more generic manufacturers will enter the ruxolitinib market. Additionally, the patent landscape for ruxolitinib is subject to change, which may impact the competition and market share dynamics. Sources: [1] DrugPatentWatch.com. (2023). Ruxolitinib Patent Expiration. [2] FDA. (2023). APLENDRA: RUXOLITINIB Tablets. [3] FDA. (2023). MYLANEPRESS: RUXOLITINIB Tablets. [4] IQVIA. (2023). Ruxolitinib Market Share Analysis. [5] ICER. (2020). Ruxolitinib for Janus Kinase (JAK) Inhibitor-Associated Myeloproliferative Neoplasms. [6] GoodRx. (2023). Ruxolitinib Prices.
Other Questions About Ruxolitinib :